All In Biotech

Drug Trial Radar · NCT04401059

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study

Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors(TKIs)in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study

Last checked: Nov 19, 2026Latest source record: Dec 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 744 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

744

Planned (sponsor's estimate)

Start

Nov 9, 2020

Primary completion

Sep 30, 2025

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Tian XieAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
LinkDoc Technology (Beijing) Co. Ltd.
First posted
May 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.

Conditions

  • Carcinoma
  • Non-Small-Cell Lung Cancer
  • Adenocarcinoma

Interventions

  • Elemene plus first or third generation EGFR-TKIsDrug

    Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label. Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason. First or third generation EGFR-TKIs: refer to the drug label.

  • First or third generation EGFR-TKIsDrug

    refer to the drug label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: Start of treatment until 1-year follow-up

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, China · Recruiting

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

  • Panjin Central Hospital

    Panjin, Liaoning, China · Recruiting

  • Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • The Second People's Hospital of Yangcheng County

    Jincheng, Shanxi, China · Recruiting

  • Sichuan Academy of Medical Sciences· Sichuan Province People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • Hangzhou Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.